Program
tulisokibart
Also written as “Tulisokibart”, “IV Tulisokibart” and “SC Tulisokibart”.
Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Panuveitis · Sarcoidosis, Pulmonary · Axial Spondyloarthritis, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 1710 open or running | phase 3since Sep 18, 2023 | Dec 9, 2020 | Feb 17, 2027phase 2 · NCT07486960 |
- Named in Merck’s own pipeline as
tulisokibart (MK-7240)
, phase 3, as of Nov 2, 2026 (source).
Also a collaborator on its studies: ppd-part-of-thermo-fisher-scientific, celerion and altasciences-company-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Dec 9, 2020.
- Feb 27, 2022Phase 2 study in Scleroderma, DiffuseNCT05270668 · 154 enrolled · United States, Argentina, Australia and more
- Apr 1, 2022Phase 1 study in HealthyNCT05354349 · 49 enrolled · United States
- Sep 18, 2023Phase 3 study in Colitis, UlcerativeNCT06052059 · 1,109 enrolled · United States, Argentina, Australia and more
- May 21, 2024Phase 3 study in Crohn DiseaseNCT06430801 · 1,200 planned · United States, Australia, Austria and more
- Aug 16, 2024Phase 1 study in HealthyNCT06575595 · 60 enrolled · United States
- Oct 18, 2024Phase 3 study in Crohn DiseaseNCT06651281 · 1,380 planned · United States, Czechia, France and more
- Feb 11, 2025Phase 1 study in Colitis, UlcerativeNCT06829225 · 48 enrolled · China
- Apr 30, 2025Phase 2 study in Hidradenitis SuppurativaNCT06956235 · 149 enrolled · United States, Argentina, Australia and more
- Aug 14, 2025Phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633 · 315 enrolled · United States, Brazil, Canada and more
- Sep 9, 2025Phase 2 study in Arthritis, RheumatoidNCT07176390 · 185 enrolled · United States, Canada, Chile and more
- Feb 5, 2026Phase 1 study in HealthyNCT07405177 · 330 enrolled · Australia
- Mar 19, 2026Phase 2 study in Arthritis, PsoriaticNCT07486960 · 140 enrolled · United States, Canada, Chile and more
- Sep 30, 2026Phase 2 study in PanuveitisNCT07861074 · 87 planned · United States, Canada
- Oct 5, 2026Phase 2 study in Sarcoidosis, PulmonaryNCT07867938 · 158 planned · United States
Ahead
- Feb 17, 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07486960
- Mar 29, 2027Primary completion: phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633
- Oct 30, 2028Primary completion: phase 3 study in Crohn DiseaseNCT06430801
- Jun 5, 2029Primary completion: phase 2 study in PanuveitisNCT07861074
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07867938Sarcoidosis, Pulmonary · United States | 2 | Recruiting | Oct 5, 2029 | 158 |
| NCT07861074Panuveitis · United States, Canada | 2 | Recruiting | Jun 5, 2029 | 87 |
| NCT07486960Arthritis, Psoriatic · United States, Canada, Chile and more | 2 | Active, not recruiting | Feb 17, 2027 | 140 |
| NCT07405177Healthy · Australia | 1 | Completed | Sep 19, 2026 | 330 |
| NCT07176390Arthritis, Rheumatoid · United States, Canada, Chile and more | 2 | Active, not recruiting | Sep 7, 2026 | 185 |
| NCT07133633Radiographic Axial Spondyloarthritis · United States, Brazil, Canada and more | 2 | Active, not recruiting | Mar 29, 2027 | 315 |
| NCT06956235Hidradenitis Suppurativa · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 2, 2026 | 149 |
| NCT06829225Colitis, Ulcerative · China | 1 | Completed | Nov 11, 2024 | 48 |
| NCT06651281Crohn Disease · United States, Czechia, France and more | 3 | Recruiting | Dec 17, 2037 | 1,380 |
| NCT06575595Healthy · United States | 1 | Completed | Jan 31, 2025 | 60 |
| NCT06430801Crohn Disease · United States, Australia, Austria and more | 3 | Recruiting | Oct 30, 2028 | 1,200 |
| NCT06052059Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 12, 2026 | 1,109 |
| NCT05354349Healthy · United States | 1 | Completed | Aug 31, 2022 | 49 |
| NCT05270668Scleroderma, Diffuse · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 16, 2026 | 154 |
| NCT05013905Crohn Disease · United States, Australia, Belgium and more | 2 | Completed | Sep 23, 2022 | 55 |
| NCT04996797Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Jun 6, 2023 | 178 |
| NCT04676178Healthy · United States | 1 | Completed | Sep 23, 2021 | 69 |
How it is read
Names in the registry
- “Tulisokibart”, 12 entries
- “IV Tulisokibart”, 2 entries
- “SC Tulisokibart”, 2 entries
- “Tulisokibart Form 1”, 1 entry
- “Tulisokibart Form 2”, 1 entry
Conditions, from the studies’ own filings
- Crohn Disease, 3 studies
- Colitis, Ulcerative, 3 studies
- Panuveitis, 1 study
- Sarcoidosis, Pulmonary, 1 study
- Axial Spondyloarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.